BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8057649)

  • 1. Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer.
    Pisters KM; Kris MG; Gralla RJ; Hilaris B; McCormack PM; Bains MS; Martini N
    J Surg Oncol; 1994 Aug; 56(4):236-41. PubMed ID: 8057649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
    Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
    J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304).
    Tada H; Tsuchiya R; Ichinose Y; Koike T; Nishizawa N; Nagai K; Kato H
    Lung Cancer; 2004 Feb; 43(2):167-73. PubMed ID: 14739037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
    J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimization of combined radiotherapy and chemotherapy in treatment of non-small cell lung carcinoma].
    Bretel JJ; Arriagada R; Le Chevalier T; Baldeyrou P; Grunenwald D; Le Péchoux C; Pellae-Cosset B; Ruffié P
    Cancer Radiother; 1997; 1(2):148-53. PubMed ID: 9273186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).
    Wada H; Miyahara R; Tanaka F; Hitomi S
    Eur J Cardiothorac Surg; 1999 Apr; 15(4):438-43. PubMed ID: 10371118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
    Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
    J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer.
    Takamori S; Rikimaru T; Hayashi A; Tayama K; Mitsuoka M; Fujimoto K; Horiuchi M; Hayabuchi N; Oizumi K; Shirouzu K
    Lung Cancer; 2000 Jul; 29(1):49-56. PubMed ID: 10880847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
    Nagai K; Tsuchiya R; Mori T; Tada H; Ichinose Y; Koike T; Kato H;
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):254-60. PubMed ID: 12579093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
    Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.
    Van den Brande P; De Ruysscher D; Vansteenkiste J; Spaas P; Specenier P; Demedts M
    Lung Cancer; 1998 Oct; 22(1):45-53. PubMed ID: 9869107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial.
    Planting A; Helle P; Drings P; Dalesio O; Kirkpatrick A; McVie G; Giaccone G
    Ann Oncol; 1996 Feb; 7(2):139-44. PubMed ID: 8777169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
    Arriagada R; Bergman B; Dunant A; Le Chevalier T; Pignon JP; Vansteenkiste J;
    N Engl J Med; 2004 Jan; 350(4):351-60. PubMed ID: 14736927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study.
    Aristu J; Rebollo J; Martínez-Monge R; Aramendía JM; Viera JC; Azinovic I; Herreros J; Brugarolas A
    Am J Clin Oncol; 1997 Jun; 20(3):276-81. PubMed ID: 9167753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer].
    Nakano K; Kumagai K; Ishida H; Kohjima N; Hiramoto T; Hada Y
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):57-61. PubMed ID: 8546470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.